824 related articles for article (PubMed ID: 26843041)
1. A Targeted Q-PCR-Based Method for Point Mutation Testing by Analyzing Circulating DNA for Cancer Management Care.
Thierry AR
Methods Mol Biol; 2016; 1392():1-16. PubMed ID: 26843041
[TBL] [Abstract][Full Text] [Related]
2. Mutation-based detection and monitoring of cell-free tumor DNA in peripheral blood of cancer patients.
Benesova L; Belsanova B; Suchanek S; Kopeckova M; Minarikova P; Lipska L; Levy M; Visokai V; Zavoral M; Minarik M
Anal Biochem; 2013 Feb; 433(2):227-34. PubMed ID: 22750103
[TBL] [Abstract][Full Text] [Related]
3. Liquid biopsy in colon cancer: comparison of different circulating DNA extraction systems following absolute quantification of
Kloten V; Rüchel N; Brüchle NO; Gasthaus J; Freudenmacher N; Steib F; Mijnes J; Eschenbruch J; Binnebösel M; Knüchel R; Dahl E
Oncotarget; 2017 Oct; 8(49):86253-86263. PubMed ID: 29156792
[TBL] [Abstract][Full Text] [Related]
4. Optimization of circulating cell-free DNA recovery for KRAS mutation and HPV detection in plasma.
Mazurek AM; Fiszer-Kierzkowska A; Rutkowski T; Składowski K; Pierzyna M; Scieglińska D; Woźniak G; Głowacki G; Kawczyński R; Małusecka E
Cancer Biomark; 2013; 13(5):385-94. PubMed ID: 24440979
[TBL] [Abstract][Full Text] [Related]
5. Circulating Cell-Free Tumor DNA Analysis of 50 Genes by Next-Generation Sequencing in the Prospective MOSCATO Trial.
Jovelet C; Ileana E; Le Deley MC; Motté N; Rosellini S; Romero A; Lefebvre C; Pedrero M; Pata-Merci N; Droin N; Deloger M; Massard C; Hollebecque A; Ferté C; Boichard A; Postel-Vinay S; Ngo-Camus M; De Baere T; Vielh P; Scoazec JY; Vassal G; Eggermont A; André F; Soria JC; Lacroix L
Clin Cancer Res; 2016 Jun; 22(12):2960-8. PubMed ID: 26758560
[TBL] [Abstract][Full Text] [Related]
6. Prospective blinded study of somatic mutation detection in cell-free DNA utilizing a targeted 54-gene next generation sequencing panel in metastatic solid tumor patients.
Kim ST; Lee WS; Lanman RB; Mortimer S; Zill OA; Kim KM; Jang KT; Kim SH; Park SH; Park JO; Park YS; Lim HY; Eltoukhy H; Kang WK; Lee WY; Kim HC; Park K; Lee J; Talasaz A
Oncotarget; 2015 Nov; 6(37):40360-9. PubMed ID: 26452027
[TBL] [Abstract][Full Text] [Related]
7. BRAF mutation analysis in circulating free tumor DNA of melanoma patients treated with BRAF inhibitors.
Gonzalez-Cao M; Mayo-de-Las-Casas C; Molina-Vila MA; De Mattos-Arruda L; Muñoz-Couselo E; Manzano JL; Cortes J; Berros JP; Drozdowskyj A; Sanmamed M; Gonzalez A; Alvarez C; Viteri S; Karachaliou N; Martin Algarra S; Bertran-Alamillo J; Jordana-Ariza N; Rosell R
Melanoma Res; 2015 Dec; 25(6):486-95. PubMed ID: 26366702
[TBL] [Abstract][Full Text] [Related]
8. Changes in mutational status during third-line treatment for metastatic colorectal cancer--results of consecutive measurement of cell free DNA, KRAS and BRAF in the plasma.
Spindler KL; Pallisgaard N; Andersen RF; Jakobsen A
Int J Cancer; 2014 Nov; 135(9):2215-22. PubMed ID: 24659028
[TBL] [Abstract][Full Text] [Related]
9. Clinical Utility of Circulating Tumor DNA for Molecular Assessment and Precision Medicine in Pancreatic Cancer.
Takai E; Totoki Y; Nakamura H; Kato M; Shibata T; Yachida S
Adv Exp Med Biol; 2016; 924():13-17. PubMed ID: 27753011
[TBL] [Abstract][Full Text] [Related]
10. Quantitative cell-free DNA, KRAS, and BRAF mutations in plasma from patients with metastatic colorectal cancer during treatment with cetuximab and irinotecan.
Spindler KL; Pallisgaard N; Vogelius I; Jakobsen A
Clin Cancer Res; 2012 Feb; 18(4):1177-85. PubMed ID: 22228631
[TBL] [Abstract][Full Text] [Related]
11. Methodological, biological and clinical aspects of circulating free DNA in metastatic colorectal cancer.
Spindler KG
Acta Oncol; 2017 Jan; 56(1):7-16. PubMed ID: 28010185
[TBL] [Abstract][Full Text] [Related]
12. Actionable mutations in plasma cell-free DNA in patients with advanced cancers referred for experimental targeted therapies.
Janku F; Angenendt P; Tsimberidou AM; Fu S; Naing A; Falchook GS; Hong DS; Holley VR; Cabrilo G; Wheler JJ; Piha-Paul SA; Zinner RG; Bedikian AY; Overman MJ; Kee BK; Kim KB; Kopetz ES; Luthra R; Diehl F; Meric-Bernstam F; Kurzrock R
Oncotarget; 2015 May; 6(14):12809-21. PubMed ID: 25980577
[TBL] [Abstract][Full Text] [Related]
13. Clinical significance of the mutational landscape and fragmentation of circulating tumor DNA in renal cell carcinoma.
Yamamoto Y; Uemura M; Fujita M; Maejima K; Koh Y; Matsushita M; Nakano K; Hayashi Y; Wang C; Ishizuya Y; Kinouchi T; Hayashi T; Matsuzaki K; Jingushi K; Kato T; Kawashima A; Ujike T; Nagahara A; Fujita K; Imamura R; Nakagawa H; Nonomura N
Cancer Sci; 2019 Feb; 110(2):617-628. PubMed ID: 30536551
[TBL] [Abstract][Full Text] [Related]
14. Genomic variations in plasma cell free DNA differentiate early stage lung cancers from normal controls.
Xia S; Huang CC; Le M; Dittmar R; Du M; Yuan T; Guo Y; Wang Y; Wang X; Tsai S; Suster S; Mackinnon AC; Wang L
Lung Cancer; 2015 Oct; 90(1):78-84. PubMed ID: 26233568
[TBL] [Abstract][Full Text] [Related]
15. Correlation of BRAF Mutation Status in Circulating-Free DNA and Tumor and Association with Clinical Outcome across Four BRAFi and MEKi Clinical Trials.
Santiago-Walker A; Gagnon R; Mazumdar J; Casey M; Long GV; Schadendorf D; Flaherty K; Kefford R; Hauschild A; Hwu P; Haney P; O'Hagan A; Carver J; Goodman V; Legos J; Martin AM
Clin Cancer Res; 2016 Feb; 22(3):567-74. PubMed ID: 26446943
[TBL] [Abstract][Full Text] [Related]
16. SiNVICT: ultra-sensitive detection of single nucleotide variants and indels in circulating tumour DNA.
Kockan C; Hach F; Sarrafi I; Bell RH; McConeghy B; Beja K; Haegert A; Wyatt AW; Volik SV; Chi KN; Collins CC; Sahinalp SC
Bioinformatics; 2017 Jan; 33(1):26-34. PubMed ID: 27531099
[TBL] [Abstract][Full Text] [Related]
17. Cell-Free DNA in Metastatic Colorectal Cancer: A Systematic Review and Meta-Analysis.
Spindler KG; Boysen AK; Pallisgård N; Johansen JS; Tabernero J; Sørensen MM; Jensen BV; Hansen TF; Sefrioui D; Andersen RF; Brandslund I; Jakobsen A
Oncologist; 2017 Sep; 22(9):1049-1055. PubMed ID: 28778958
[TBL] [Abstract][Full Text] [Related]
18. A Comparison of Cell-Free DNA Isolation Kits: Isolation and Quantification of Cell-Free DNA in Plasma.
Sorber L; Zwaenepoel K; Deschoolmeester V; Roeyen G; Lardon F; Rolfo C; Pauwels P
J Mol Diagn; 2017 Jan; 19(1):162-168. PubMed ID: 27865784
[TBL] [Abstract][Full Text] [Related]
19. Development and Validation of an Ultradeep Next-Generation Sequencing Assay for Testing of Plasma Cell-Free DNA from Patients with Advanced Cancer.
Janku F; Zhang S; Waters J; Liu L; Huang HJ; Subbiah V; Hong DS; Karp DD; Fu S; Cai X; Ramzanali NM; Madwani K; Cabrilo G; Andrews DL; Zhao Y; Javle M; Kopetz ES; Luthra R; Kim HJ; Gnerre S; Satya RV; Chuang HY; Kruglyak KM; Toung J; Zhao C; Shen R; Heymach JV; Meric-Bernstam F; Mills GB; Fan JB; Salathia NS
Clin Cancer Res; 2017 Sep; 23(18):5648-5656. PubMed ID: 28536309
[No Abstract] [Full Text] [Related]
20. Multiplex detection of ctDNA mutations in plasma of colorectal cancer patients by PCR/SERS assay.
Lyu N; Rajendran VK; Diefenbach RJ; Charles K; Clarke SJ; Engel A; ; Rizos H; Molloy MP; Wang Y
Nanotheranostics; 2020; 4(4):224-232. PubMed ID: 32923312
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]